Live·Open questions in longevity research
All news
Biotech fundingIndustry & policy

California approves $8.4 billion in borrowing for immunology research, with only one institute meeting the legal criteria for half the funding: an institute co-founded by the measure’s author, Gary Michelson

11 November 2026· 261111002

California approves $8.4 billion in borrowing for immunology research, with only one institute meeting the legal criteria for half the funding: an institute co-founded by the measure’s author, Gary Michelson

Proposition 38 went before voters on November 3, and the Associated Press called it approved on November 9, with preliminary results showing about 54% in favor. The measure authorizes the state to borrow money for research into immunity and immunotherapy, treatments that direct the immune system to fight disease. At least $4.2 billion must fund immunology research on cancer, heart disease, and Alzheimer’s disease; half the total will go to a single institute selected by the Department of Public Health, and the rest will be distributed through grants.

Nature reports that US voters have never approved so much money for science. The California Institute for Regenerative Medicine provides a precedent: in 2004, after President Bush restricted federal funding for embryonic stem cell research, voters approved $3 billion in borrowing to establish it, then added $5.5 billion in 2020.

In a 2025 interview, Michelson explained why he was backing immunology: what chronic diseases share is that “our own immune system mediates every one of them.” He is a co-founder of the California Institute for Immunology and Immunotherapy (CIII), which is affiliated with the University of California, Los Angeles (UCLA). In August 2024, Michelson and his wife pledged $120 million to the institute. By the end of October, the campaign supporting the measure had raised $71.2 million, including $66.2 million from Michelson and his organizations; the opposition campaign had raised about $12 thousand.

The law’s requirements for the recipient of half the funding include an agreement with a University of California campus whose clinics handle more than 3.5 million patient visits a year, and pledged donations of at least $50 million for each of two programs: rapid vaccine development and research on microbes in the human body. The initiative was filed in October 2025, but the law requires both the institute and its agreement with the campus to have been in place by January 1, 2025. Only an institute already operating by that date could qualify.

According to reporting by CalMatters, just one institute qualifies: CIII. Only UCLA exceeds the threshold of 3.5 million patient visits (the San Francisco campus records 3.4 million), and the law describes the two $50 million programs in almost the same words as the press release announcing the Michelsons’ gift. Robin Swanson of the campaign supporting the measure said: “It is highly likely that CIII … will qualify for half the funding under the current criteria.” Microbiologist Jonathan Eisen of the University of California, Davis, had never seen “a competition for proposals to establish a center look even remotely this predetermined.”

The campaign supporting the measure says the criteria ensure that the recipient can accelerate research immediately because it already has the resources, a site, and a university affiliation. In September 2026, CIII had three employees, although plans had called for about 51 by summer 2025.

The other half will be distributed as grants by a board representing seven university campuses and 10–15 other organizations, with recipients selected from those same institutions. The borrowing will be repaid from the state budget: the state’s Legislative Analyst estimates annual payments of $500–600 million for about 20 years, totaling up to $12 billion with interest. Recipients must pay the state 10% of revenue generated by the research until those payments cover the borrowing. Robert Kaplan, co-chair of the opposition campaign, calculated that repaying $12 billion from a 10% share would require $120 billion in revenue. Research funded by the earlier stem cell borrowing has generated about $16 million in licensing payments, less than 1% of the debt including interest.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#proposition-38#immunology#research-bonds#gary-michelson#california#public-funding